MCID: GLY007
MIFTS: 48

Glycogen Storage Disease Iv malady

Genetic diseases, Rare diseases, Metabolic diseases, Liver diseases, Cardiovascular diseases, Endocrine diseases categories

Aliases & Classifications for Glycogen Storage Disease Iv

About this section

Aliases & Descriptions for Glycogen Storage Disease Iv:

Name: Glycogen Storage Disease Iv 49 10 11 21 23 12 67
Glycogen Storage Disease Type Iv 21 45 23 47 65 36
Glycogen Branching Enzyme Deficiency 21 45 22 23 67
Andersen Disease 21 45 22 23 67
Glycogen Storage Disease Type 4 45 22 23 24
Amylopectinosis 10 45 23 67
Gsd Iv 21 45 23 67
Glycogenosis 4 45 22 23
Brancher Deficiency 45 23
Glycogenosis Iv 21 67
Gsd 4 45 22
Gsd4 23 67
Cirrhosis, Familial, with Deposition of Abnormal Glycogen 45
Deficiency of 1,4-Alpha-Glucan Branching Enzyme 10
 
Branching-Transferase Deficiency Glycogenosis 10
Glycogen Storage Disease, Type Iv 10
Brancher Deficiency Glycogenosis 10
Branching Enzyme Deficiency 23
Glycogen Storage Disease 4 67
Glycogenosis, Type Iv 23
Andersen Glycogenosis 23
Type Iv Glycogenosis 23
Andersen's Disease 23
Gbe1 Deficiency 67
Gsd Type Iv 23
Gsd-Iv 67
Gsdiv 22


Classifications:



Summaries for Glycogen Storage Disease Iv

About this section
NIH Rare Diseases:45 Glycogen storage disease type 4 (gsd 4) is part of a group of disorders which lead to abnormal accumulation of glycogen (a storage form of glucose) in various parts of the body. symptoms of gsd 4 usually begin in infancy and typically include failure to thrive; enlarged liver and spleen (hepatosplenomegaly); and in many cases, progressive liver cirrhosis and liver failure. in rare cases individuals may have a form with non-progressive liver disease, or a severe neuromuscular form. gsd 4 is caused by mutations in the gbe1 gene and is inherited in an autosomal recessive manner. treatment typically focuses on the specific symptoms that are present in each individual. last updated: 12/23/2012

MalaCards based summary: Glycogen Storage Disease Iv, also known as glycogen storage disease type iv, is related to glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form and glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form, and has symptoms including autosomal recessive inheritance, edema and muscular hypotonia. An important gene associated with Glycogen Storage Disease Iv is GBE1 (Glucan (1,4-Alpha-), Branching Enzyme 1), and among its related pathways are Galactose metabolism and Glucose metabolism. Affiliated tissues include liver, spleen and skeletal muscle.

Genetics Home Reference:23 Glycogen storage disease type IV (GSD IV) is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulated glycogen is structurally abnormal and impairs the function of certain organs and tissues, especially the liver and muscles. There are five types of GSD IV, which are distinguished by their severity, signs, and symptoms.

UniProtKB/Swiss-Prot:67 Glycogen storage disease 4: A metabolic disorder characterized by the accumulation of an amylopectin-like polysaccharide. The typical clinical manifestation is liver disease of childhood, progressing to lethal hepatic cirrhosis. Most children with this condition die before two years of age. However, the liver disease is not always progressive. No treatment apart from liver transplantation has been found to prevent progression of the disease. There is also a neuromuscular form of glycogen storage disease type 4 that varies in onset (perinatal, congenital, juvenile, or adult) and severity.

Wikipedia:68 Glycogen storage disease type IV is a rare hereditary metabolic disorder. It is the result of a mutation... more...

Description from OMIM:49 232500

GeneReviews summary for gsd4

Related Diseases for Glycogen Storage Disease Iv

About this section

Diseases in the Glycogen Storage Disease family:

Glycogen Storage Disease Iiia glycogen storage disease iv
Glycogen Storage Disease Xv Glycogen Storage Disease X
Glycogen Storage Disease Ib Glycogen Storage Disease Ic
Glycogen Storage Disease Vii Glycogen Storage Disease Vi
Glycogen Storage Disease Ixc Glycogen Storage Disease Xii
Glycogen Storage Disease Xiii Glycogen Storage Disease Ia
Glycogen Storage Disease Ii Glycogen Storage Disease Ix
Glycogen Storage Disease Viii Glycogen Storage Disease Type 0

Diseases related to Glycogen Storage Disease Iv via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
idRelated DiseaseScoreTop Affiliating Genes
1glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form10.6
2glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form10.6
3glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form10.6
4glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form10.6
5glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form10.6
6glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form10.6
7glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form10.6
8glycogen storage disease10.6
9autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis10.3
10n syndrome10.3
11andersen syndrome10.3
12child syndrome10.3
13hepatitis10.3
14nelson syndrome10.3
15hepatocellular adenoma10.3
16adenoma10.3
17carbohydrate metabolic disorder10.3
18congenital heart disease10.3
19long qt syndrome10.3
20nutritional deficiency disease10.3
21hydrops fetalis10.3
22kid syndrome10.3
23hypotonia10.3
24glycogen storage disease due to glycogen branching enzyme deficiency10.3
25adult polyglucosan body disease10.3
26infantile hypotonia10.1
27cardiomyopathy10.1
28glycogen storage disease vi10.1
29neutropenia, severe congenital 4, autosomal recessive9.9G6PC, GBE1
30aryepiglottic fold cancer9.9CPT2, G6PC
31leydig cell hypoplasia due to lhb deficiency9.9RBCK1, RNF31
32glycogen storage disease iiia9.9G6PC, GAA, GBE1
33cardiovascular organ benign neoplasm9.8G6PC, GAA, GBE1
34ceroid lipofuscinosis, neuronal, 13, kufs type9.8CPT2, GAA
35granuloma annulare9.8G6PC, GAA, GBE1
36glycogen storage disease iv9.1CPT2, G6PC, GAA, GBE1, RBCK1, RNF31

Graphical network of the top 20 diseases related to Glycogen Storage Disease Iv:



Diseases related to glycogen storage disease iv

Symptoms for Glycogen Storage Disease Iv

About this section

Symptoms by clinical synopsis from OMIM:

232500

Clinical features from OMIM:

232500

HPO human phenotypes related to Glycogen Storage Disease Iv:

(show all 19)
id Description Frequency HPO Source Accession
1 autosomal recessive inheritance HP:0000007
2 edema HP:0000969
3 muscular hypotonia HP:0001252
4 reduced tendon reflexes HP:0001315
5 muscle weakness HP:0001324
6 cirrhosis HP:0001394
7 hepatic failure HP:0001399
8 portal hypertension HP:0001409
9 hepatosplenomegaly HP:0001433
10 failure to thrive HP:0001508
11 ascites HP:0001541
12 decreased fetal movement HP:0001558
13 polyhydramnios HP:0001561
14 cardiomyopathy HP:0001638
15 hydrops fetalis HP:0001789
16 esophageal varix HP:0002040
17 arthrogryposis multiplex congenita HP:0002804
18 skeletal muscle atrophy HP:0003202
19 tubulointerstitial fibrosis HP:0005576

Drugs & Therapeutics for Glycogen Storage Disease Iv

About this section

Drugs for Glycogen Storage Disease Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
rituximabapprovedPhase 41514174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
2
MethotrexateapprovedPhase 413871959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
3
Bortezomibapproved, investigational, experimentalPhase 4758179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
4
Cyclophosphamideapproved, investigationalPhase 4252550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
Folic Acidapproved, nutraceuticalPhase 4285159-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
6Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 1, Phase 2749
7AlbuterolPhase 4, Phase 1, Phase 2465
8Vitamin B ComplexPhase 42775
9Rho(D) Immune GlobulinPhase 4198
10Glucagon-Like Peptide 1Phase 4652
11Immunoglobulins, IntravenousPhase 4203
12glucagonPhase 4415
13FolateNutraceuticalPhase 42851
14Vitamin B9NutraceuticalPhase 42851
15Folinic AcidNutraceuticalPhase 42498
16
MiglustatapprovedPhase 12072599-27-051634
Synonyms:
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
1,5-Dideoxy-1,5-N-butylimino-D-glucitol
134282-77-2
72599-27-0
AC1L1BHJ
BuDNJ
Butyldeoxynojirimycin
CHEBI:49779
CHEBI:50381
CHEMBL1029
CID51634
D05032
DB00419
HMS2090N20
LS-116261
Miglustat
Miglustat (USAN/INN)
Miglustat Hydrochloride
Miglustat [USAN]
Miglustat, Hydrochloride
Miglustatum
N-(N-Butyl)deoxynojirimycin
N-(n-Butyl)deoxynojirimycin
N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol
 
N-Bu-DNJ
N-Butyl deoxynojirimycin
N-Butyl-1-deoxynojirimycin
N-Butyl-DNJ
N-Butyl-deoxynojirimycin
N-Butyldeoxynojirimycin
N-Butylmoranoline
N-butyl-1-deoxynojirimycin
NB-DNJ
NB-dnj
NBV
OGT 918
OGT-918
SC 48334
SC-48334
SC48334
UNII-ADN3S497AZ
Vevesca
Zavesca
Zavesca (TN)
miglustatum
n-Butyl deoxynojirimycin
n-Butyl dnj
nchembio.81-comp12
nchembio850-comp5
17
AcetazolamideapprovedPhase 16159-66-51986
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2h4n
3czv
4-Diamox
5-ACETAMIDO-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5661-25-6
59-66-5
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
AI3-52458
AKOS000715163
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
Acetazolamide
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide Apotex Brand
Acetazolamide Chiesi Brand
Acetazolamide Dioptic Brand
Acetazolamide Grin Brand
Acetazolamide ICN Brand
Acetazolamide Jumer Brand
Acetazolamide Llorens Brand
Acetazolamide Medphano Brand
Acetazolamide Novopharm Brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide Sodium, (Sterile)
Acetazolamide Wassermann Brand
Acetazolamide [INN:BAN:JAN]
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
Acétazolamide
Ak Zol
Ak-Zol
AkZol
Apo Acetazolamide
Apo-Acetazolamide
ApoAcetazolamide
Apotex Brand of Acetazolamide
Atenezol
Avva
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
CID1986
CPD0-1626
CPD000058394
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
Carbonic anhydrase inhibitor 6063
Chiesi Brand of Acetazolamide
Ciba Vision Brand of Acetazolamide
Cidamex
D000086
D00218
DB00819
Dazamide
Defiltran
Dehydratin
Diacarb
Diakarb
Diamox
Diamox (TN)
Diamox Sequels
Didoc
 
Diluran
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-Holzinger
Diureticum-holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
EINECS 200-440-5
EU-0100039
Edemox
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma Zolamide
Huma-Zolamide
HumaZolamide
I09-0425
ICN Brand of Acetazolamide
IDI1_000017
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
LS-10227
Llorens Brand of Acetazolamide
Lopac-A-6011
Lopac0_000039
MLS000028435
MLS001148438
Medphano Brand of Acetazolamide
MolPort-001-783-578
Monosodium Salt Acetazolamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
NINDS_000017
NSC 145177
NSC145177
Natrionex
Nephramid
Nephramide
Novopharm Brand of Acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
Prestwick_4
SAM002554883
SBB056640
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
SPECTRUM1500102
Sk-Acetazolamide
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Spectrum_000018
Storz Brand of Acetazolamide Preparation
Storzolamide
UNII-O3FX965V0I
Vetamox
WLN: T5NN DSJ CSZW EMV1
Wassermann Brand of Acetazolamide
Wyeth Brand of Acetazolamide Preparation
acetazolamide
18
AcetylcholineexperimentalPhase 010451-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
19Pyridostigmine BromidePhase 022101-26-8
20BromidesPhase 0355

Interventional clinical trials:

(show all 41)
idNameStatusNCT IDPhase
1Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase AlfaCompletedNCT01288027Phase 4
2An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseaseCompletedNCT00701129Phase 4
3Late-Onset Treatment Study Extension ProtocolCompletedNCT00455195Phase 4
4High Dose or High Dose Frequency Study of Alglucosidase AlfaCompletedNCT00483379Phase 4
5Immune Tolerance Induction StudyRecruitingNCT00701701Phase 4
6Pompe Pregnancy Sub-RegistryRecruitingNCT00567073Phase 4
7Pharmacokinetics of Alglucosidase Alfa in Patients Aged 8-18 Years of AgeRecruitingNCT01410890Phase 4
8Pompe Lactation Sub-RegistryRecruitingNCT00566878Phase 4
9Evaluation of Salbutamol as an Adjuvant Therapy for Pompe DiseaseRecruitingNCT02405598Phase 4
10CPAP for Infantile Pompe DiseaseRecruitingNCT02405624Phase 4
11Immune Modulation Therapy for Pompe DiseaseRecruitingNCT02525172Phase 4
12Glucagon Efficiency After High and Low Carbohydrate DietRecruitingNCT02578498Phase 4
13Growth and Development Study of Alglucosidase Alfa.Active, not recruitingNCT00486889Phase 4
14A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe DiseaseTerminatedNCT01597596Phase 4
15A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseaseTerminatedNCT01526785Phase 4
16A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe DiseaseCompletedNCT00158600Phase 3
17NeoGAA Extension StudyRecruitingNCT02032524Phase 2, Phase 3
18BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)RecruitingNCT01924845Phase 3
19Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body DiseaseCompletedNCT00947960Phase 2
20Drug-drug Interaction StudyCompletedNCT01380743Phase 2
21Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe DiseaseCompletedNCT00976352Phase 1, Phase 2
22Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe DiseaseCompletedNCT01230801Phase 1, Phase 2
23Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement TherapyActive, not recruitingNCT01885936Phase 1, Phase 2
24Extension Study for Patients Who Have Participated in a BMN 701 StudyActive, not recruitingNCT01435772Phase 2
25Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.CompletedNCT01898364Phase 1
26Albuterol in Individuals With Late Onset Pompe Disease (LOPD)CompletedNCT01859624Phase 1
27A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated ReactionRecruitingNCT02185651Phase 1
28Effect of Potassium and Acetazolamide on People With Andersen-Tawil SyndromeTerminatedNCT00839501Phase 1
29A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human VolunteersWithdrawnNCT01039909Phase 1
30Alglucosidase Alfa Temporary Access ProgramApproved for marketingNCT00520143
31Characteristics of Andersen-Tawil SyndromeCompletedNCT00521794
32Glycogen Storage Disease Type IV DatabaseRecruitingNCT02683512
33Biomarker for Glycogen Storage DiseasesRecruitingNCT02385162
34Energy Supplements to Improve Exercise Tolerance in Metabolic MyopathiesRecruitingNCT02448667
35Prospective Follow-up of Patients With Glycogen Storage Disease Type IIIRecruitingNCT01563705
36Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.RecruitingNCT02654886
37A Pilot Study of Pyridostigmine in Pompe DiseaseRecruitingNCT02357225Phase 0
38Alglucosidase Alfa Pompe Safety Sub-RegistryRecruitingNCT01710813
39Fat and Sugar Metabolism During Exercise in Patients With Metabolic MyopathyNot yet recruitingNCT02635269
40Diet and Exercise in Pompe DiseaseNot yet recruitingNCT02363153Phase 0
41Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emiaNot yet recruitingNCT01482494

Search NIH Clinical Center for Glycogen Storage Disease Iv


Cochrane evidence based reviews: Glycogen Storage Disease Type IV

Genetic Tests for Glycogen Storage Disease Iv

About this section

Genetic tests related to Glycogen Storage Disease Iv:

id Genetic test Affiliating Genes
1 Glycogen Storage Disease Type Iv22 GBE1
2 Glycogen Storage Disease, Type Iv24

Anatomical Context for Glycogen Storage Disease Iv

About this section

MalaCards organs/tissues related to Glycogen Storage Disease Iv:

33
Liver, Spleen, Skeletal muscle

Animal Models for Glycogen Storage Disease Iv or affiliated genes

About this section

Publications for Glycogen Storage Disease Iv

About this section

Articles related to Glycogen Storage Disease Iv:

idTitleAuthorsYear
1
Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV. (21075835)
2011
2
Anesthetic management in a child with Glycogen Storage Disease IV. (20519014)
2010
3
Glycogen branching enzyme (GBE1) mutation causing equine glycogen storage disease IV. (15366377)
2004
4
Genetic mapping of GBE1 and its association with glycogen storage disease IV in American Quarter horses. (14970703)
2003
5
Studies in glycogen storage disease. IV. Leukocyte phosphorylase in a family with type VI GSD. (4313495)
1970

Variations for Glycogen Storage Disease Iv

About this section

UniProtKB/Swiss-Prot genetic disease variations for Glycogen Storage Disease Iv:

67
id Symbol AA change Variation ID SNP ID
1GBE1p.Leu224ProVAR_022429
2GBE1p.Phe257LeuVAR_022430
3GBE1p.Tyr329SerVAR_022431
4GBE1p.Arg515CysVAR_022432
5GBE1p.Arg524GlnVAR_022434
6GBE1p.His545ArgVAR_022435
7GBE1p.His628ArgVAR_022436

Clinvar genetic disease variations for Glycogen Storage Disease Iv:

5 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1GBE1NM_000158.3(GBE1): c.691+2T> Csingle nucleotide variantPathogenicrs192044702GRCh37Chr 3, 81698005: 81698005
2GBE1NM_000158.3(GBE1): c.986A> C (p.Tyr329Ser)single nucleotide variantPathogenicrs80338671GRCh37Chr 3, 81691938: 81691938
3GBE1NM_000158.3(GBE1): c.671T> C (p.Leu224Pro)single nucleotide variantPathogenicrs137852886GRCh37Chr 3, 81698027: 81698027
4GBE1NM_000158.3(GBE1): c.1543C> T (p.Arg515Cys)single nucleotide variantPathogenicrs80338672GRCh37Chr 3, 81627151: 81627151
5GBE1NM_000158.3(GBE1): c.771T> A (p.Phe257Leu)single nucleotide variantPathogenicrs137852887GRCh37Chr 3, 81695554: 81695554
6GBE1NM_000158.3(GBE1): c.1570C> T (p.Arg524Ter)single nucleotide variantPathogenicrs137852888GRCh37Chr 3, 81627124: 81627124
7GBE1NM_000158.3(GBE1): c.1571G> A (p.Arg524Gln)single nucleotide variantPathogenicrs80338673GRCh37Chr 3, 81627123: 81627123
8GBE1NM_000158.3(GBE1): c.993-?_1618+?deldeletionPathogenicGRCh37Chr 3, 81586246: 81691932
9GBE1NM_000158.3(GBE1): c.143+1G> Asingle nucleotide variantPathogenicrs397515343GRCh37Chr 3, 81810525: 81810525
10GBE1NM_000158.3(GBE1): c.1634A> G (p.His545Arg)single nucleotide variantPathogenicrs137852889GRCh37Chr 3, 81586231: 81586231
11GBE1NM_000158.3(GBE1): c.1774G> T (p.Glu592Ter)single nucleotide variantPathogenicrs137852890GRCh37Chr 3, 81586091: 81586091
12GBE1NM_000158.3(GBE1): c.1883A> G (p.His628Arg)single nucleotide variantPathogenicrs137852891GRCh37Chr 3, 81584397: 81584397
13GBE1NM_000158.3(GBE1): c.691+5G> Csingle nucleotide variantPathogenicrs397515344GRCh37Chr 3, 81698002: 81698002
14GBE1NM_000158.3(GBE1): c.1643G> A (p.Trp548Ter)single nucleotide variantPathogenicrs137852894GRCh37Chr 3, 81586222: 81586222
15c.[708G> C]+[784C> T]undetermined variantPathogenic
16c.[c.38dupA]+[1571G> A]duplicationPathogenic

Expression for genes affiliated with Glycogen Storage Disease Iv

About this section
Search GEO for disease gene expression data for Glycogen Storage Disease Iv.

Pathways for genes affiliated with Glycogen Storage Disease Iv

About this section

Pathways related to Glycogen Storage Disease Iv according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.5G6PC, GAA
2
Show member pathways
9.1G6PC, GAA, GBE1
3
Show member pathways
9.1G6PC, GAA, GBE1
4
Show member pathways
9.1G6PC, GAA, GBE1

GO Terms for genes affiliated with Glycogen Storage Disease Iv

About this section

Cellular components related to Glycogen Storage Disease Iv according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1LUBAC complexGO:00717979.1RBCK1, RNF31

Biological processes related to Glycogen Storage Disease Iv according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1glucose metabolic processGO:000600610.0GAA, GBE1
2glycogen catabolic processGO:000598010.0G6PC, GAA
3protein linear polyubiquitinationGO:00970399.8RBCK1, RNF31
4glycogen metabolic processGO:00059779.7G6PC, GAA, GBE1
5regulation of tumor necrosis factor-mediated signaling pathwayGO:00108039.7RBCK1, RNF31
6I-kappaB kinase/NF-kappaB signalingGO:00072499.7RBCK1, RNF31
7T cell receptor signaling pathwayGO:00508529.6RBCK1, RNF31
8tumor necrosis factor-mediated signaling pathwayGO:00332099.6RBCK1, RNF31
9positive regulation of I-kappaB kinase/NF-kappaB signalingGO:00431239.6RBCK1, RNF31
10positive regulation of NF-kappaB transcription factor activityGO:00510929.6RBCK1, RNF31
11carbohydrate metabolic processGO:00059759.3G6PC, GAA, GBE1
12protein polyubiquitinationGO:00002099.1RBCK1, RNF31
13small molecule metabolic processGO:00442818.2CPT2, G6PC, GAA, GBE1

Molecular functions related to Glycogen Storage Disease Iv according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1hydrolase activity, hydrolyzing O-glycosyl compoundsGO:00045539.8GAA, GBE1
2catalytic activityGO:00038249.1G6PC, GAA, GBE1
3ubiquitin bindingGO:00431308.8RBCK1, RNF31

Sources for Glycogen Storage Disease Iv

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet